Pharmafile Logo
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • - PMLiVE
  • Communiqué 53 Cover Image

delamanid

- PMLiVE

J&J’s multidrug-resistant TB treatment Sirturo granted full EC and FDA approvals

An estimated 410,000 people globally developed multidrug- or rifampicin-resistant TB in 2022

- PMLiVE

Gates Foundation and Wellcome to fund late-stage trial of tuberculosis vaccine candidate

If proven effective, M72 could be the first new tuberculosis vaccine in over a century

- PMLiVE

Gates MRI and Calibr announce licensing agreement for tuberculosis treatment

TB is a severe disease responsible for an estimated 1.5 million deaths per year

- PMLiVE

WHO to establish tuberculosis vaccine accelerator council

An estimated 10.6 million contracted TB in 2021, with the disease causing 1.6 million deaths

- PMLiVE

WHO reveals tuberculosis deaths rose due to COVID-19 disruption

An estimated 10.6 million were infected with TB in 2021, an increase of 4.5% from 2020

- PMLiVE

Merck and Bill & Melinda Gates Institute sign licensing agreement for tuberculosis candidates

The non-profit will determine their potential for inclusion in new affordable treatment regimens

- PMLiVE

Roche collaborates with Global Fund to strengthen critical diagnostics infrastructure

The partnership is focused on helping patients with HIV and TB in low- and middle-income countries

- PMLiVE

GSK licenses its tuberculosis vaccine to Gates MRI

Vaccine has demonstrated around 50% efficacy in preventing disease

- PMLiVE

Merck strengthens KRAS stake with Taiho and Astex partnership

Partner companies could gain $2.5bn in milestone payments

- PMLiVE

Otsuka presses on with Alzheimer’s agitation drug

Surprise announcement comes on the heels of phase 3 trial fail

- PMLiVE

GSK’s pivotal TB vaccine could prevent millions of deaths

Key study took place in TB-endemic regions, testing 3,500 participants

- PMLiVE

J&J pledges $500m investment into HIV and tuberculosis R&D

Aims to help eliminate both diseases by 2030

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links